Clinical significance of myositis-specific autoantibodies

Nakashima, Ran

doi:10.1080/25785826.2018.1531188

Cited by 37 publications

(40 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased evidences suggest a possible specific disease subset for each antibody specificity [107]. Anti-Mi2 and antibodies to small ubiquitin-like modifier activating enzyme (anti-SAE) are associated with the diagnosis of juvenile DM and skin involvement in DM, respectively, but both myositis and ILD seem to have a good prognosis when associated to these antibodies [108]. The most dangerous MSAs can be considered anti-Melanoma Differentiation-Associated 5 gene (anti-MDA5), generally associated with clinically amyopathic DM and rapidly progressive ILD [109].…”

Section: Second-line Autoimmunity Examsmentioning

confidence: 99%

Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?

Sambataro

Pignataro³

et al. 2020

Diagnostics

View full text Add to dashboard Cite

The diagnostic assessment of patients with Interstitial Lung Disease (ILD) can be challenging due to the large number of possible causes. Moreover, the diagnostic approach can be limited by the severity of the disease, which may not allow invasive exams. To overcome this issue, the referral centers for ILD organized Multidisciplinary Teams (MDTs), including physicians and experts in complementary discipline, to discuss the management of doubtful cases of ILD. MDT is currently considered the gold standard for ILD diagnosis, but it is not often simple to organize and, furthermore, rheumatologists are still not always included. In fact, even if rheumatologic conditions represent a common cause of ILD, they are sometimes difficult to recognize, considering the variegated clinical features and their association with all possible radiographic patterns of ILD. The first objective of this review is to describe the clinical, laboratory, and instrumental tests that can drive a diagnosis toward a possible rheumatic disease. The secondary objective is to propose a set of first-line tests to perform in all patients in order to recognize any possible rheumatic conditions underlying ILD.

show abstract

Section: Second-line Autoimmunity Examsmentioning

confidence: 99%

Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?

Sambataro

Pignataro³

et al. 2020

Diagnostics

View full text Add to dashboard Cite

show abstract

“…Interestingly, 66% of anti-Zo positive ASS showed reactivity against anti-Ro52 [29]. It is known that patients with both Ro52 and t-RNA synthase antibodies are characterized by chronic and severe ILD [6,19]. Possibly, patients with combined Ro52 and Zoα antibodies show similar clinical outcomes.…”

Section: Discussionmentioning

confidence: 99%

“…Antibodies specific for t-RNA synthetases have been thoroughly described in myopathies and CTD-ILDs, but were also identified in other ILDs including IPF [ 3 , 4 , 5 , 6 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 ]. Ha antibodies are seen in myopathies and in 40% of Ssc [ 28 , 35 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

“…Serologic testing for autoantibodies by a myositis blot is recommended in pulmonary fibrosis suspected for an underlying CTD, which includes myositis specific antibodies (MSA) and myositis associated antibodies (MAA) [ 1 , 3 , 4 , 6 , 11 , 12 , 13 , 14 , 15 , 16 ]. MSA and MAA are found in patients with idiopathic interstitial myopathies but also occur in patients with rheumatic diseases including CTD-ILDs [ 3 , 4 , 5 , 6 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ]. Moreover, myositis antibody positivity has been described in other ILDs, including hypersensitivity pneumonitis (HP) and idiopathic IPs [ 11 , 16 , 23 , 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease

Moll

Platenburg

Platteel

et al. 2020

JCM

View full text Add to dashboard Cite

Connective tissue diseases (CTDs) are an important secondary cause of interstitial lung disease (ILD). If a CTD is suspected, clinicians are recommended to perform autoantibody testing, including for myositis autoantibodies. In this study, the prevalence and clinical associations of novel myositis autoantibodies in ILD are presented. A total of 1194 patients with ILD and 116 healthy subjects were tested for antibodies specific for Ks, Ha, Zoα, and cN1A with a line-blot assay on serum available at the time of diagnosis. Autoantibodies were demonstrated in 63 (5.3%) patients and one (0.9%) healthy control (p = 0.035). Autoantibodies were found more frequently in females (p = 0.042) and patients without a histological and/or radiological usual interstitial pneumonia (UIP; p = 0.010) and a trend towards CTD-ILDs (8.4%) was seen compared with other ILDs (4.9%; p = 0.090). The prevalence of antibodies specific for Ks, Ha, Zoα, and cN1A was, respectively, 1.3%, 2.0%, 1.4%, and 0.9% in ILD. Anti-Ha and Anti-Ks were observed in males with unclassifiable idiopathic interstitial pneumonia (unclassifiable IIP), hypersensitivity pneumonitis (HP), and various CTD-ILDs, whereas anti-cN1A was seen in females with antisynthetase syndrome (ASS), HP, and idiopathic pulmonary fibrosis (IPF). Anti-Zoα was associated with CTD-ILD (OR 2.5; 95%CI 1.11–5.61; p = 0.027). In conclusion, a relatively high prevalence of previously unknown myositis autoantibodies was found in a large cohort of various ILDs. Our results contribute to the awareness that circulating autoantibodies can be found in ILDs with or without established CTD. Whether these antibodies have to be added to the standard set of autoantibodies analysed in conventional myositis blot assays for diagnostic purposes in clinical ILD care requires further study.

show abstract

“…However, we observed higher sST2 concentrations in anti-SRP-positive patients, what to our knowledge has not been stated before. Signal Recognition Particle (SRP) regulates transport of proteins through the endoplasmic reticulum membrane [18]. Antibodies targeting this protein-RNA complex are associated with poor response to treatment and might have been related to cardiac complication.…”

Section: Discussionmentioning

confidence: 99%

Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study

et al. 2020

View full text Add to dashboard Cite

Idiopathic inflammatory myopathies (IIM) are rare connective tissue diseases, which can lead to internal organ involvement. IL-33/ST2 pathway is involved in the pathogenesis of numerous diseases including autoimmune disorders. IL-33 fulfils cardioprotective function, while soluble ST2 (sST2) is a decoy receptor that reduces protective impact of IL-33. The aim of the study was to evaluate the concentrations of sST2 and IL-33 in sera of patients with IIM and evaluate its associations with the clinical course of the disease. Patients with IIM as well as age-and sex-matched healthy controls were recruited. Concentrations of sST2 and IL-33 were assessed with ELISA in sera of both patients and controls. Patients were asked to fill in the questionnaires concerning clinical symptoms and physical functioning. Concentrations of sST2 and IL-33 were correlated with the results of laboratory tests and clinical symptoms. Concentrations of sST2 were significantly higher in IIM group than in healthy subjects (median sST2 in IIM 26.51 vs in healthy controls 21.39; p = 0.03). In the majority of patients, IL-33 concentrations did not exceed the detection limit. Anti-SRP-positive patients presented significantly higher concentrations of sST2 as compared to anti-SRP-negative patients (p = 0.04). In patients with anti-Ro52 antibodies, sST2 concentrations were significantly lower than in anti-Ro52-negative patients (p = 0.02). Concentrations of sST2 correlated with the degree of disability evaluated with Health Assessment Questionnaire. sST2 is increased in patients with IIM and its concentration correlates with the degree of disability. In patients with anti-SRP antibodies, levels of sST2 are exceptionally high. KeywordsIdiopathic inflammatory myopathy · ST2 · IL-33 · Myositis Rheumatology INTERNATIONAL Electronic supplementary material The online version of this article (https ://doi.org/10.

show abstract

Clinical significance of myositis-specific autoantibodies

Cited by 37 publications

References 107 publications

Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?

Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?

Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease

Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study

Contact Info

Product

Resources

About